BiQ: Jazz Pharmaceuticals Buys Chimerix (CMRX)

In addition to the strong run for Heron Therapeutics (HRTX) after the company announced Q4 earnings last week, BiQ members received some more good news this morning as Chimerix announced a buyout by Jazz Pharmaceuticals at a share price of $8.55/sh, or approximately a 70% premium to the most recent pre-buyout share price. I never invest in buyout strategies; the investment in CMRX was driven by its high long-term upside potential with limited downside risk. Still, this buyout was a complete surprise to me--as was the bittersweet buyout price. However, with market conditions being what they are, I am still delighted with the win.

Attached below is the final iQ Cheat Sheet for Chimerix, which was provided to Premium members when the company was added to the BiQ Active Portfolio and was last updated on February 18, 2025.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.